Your browser is no longer supported. Please, upgrade your browser.
CYAD Celyad SA daily Stock Chart
Celyad SA
Index- P/E- EPS (ttm)-7.01 Insider Own0.09% Shs Outstand11.94M Perf Week-2.17%
Market Cap268.58M Forward P/E- EPS next Y- Insider Trans- Shs Float9.04M Perf Month5.84%
Income- PEG- EPS next Q- Inst Own6.71% Short Float0.90% Perf Quarter-18.22%
Sales2.97M P/S90.31 EPS this Y- Inst Trans- Short Ratio9.26 Perf Half Y-22.21%
Book/sh7.09 P/B3.17 EPS next Y- ROA- Target Price49.20 Perf Year-50.24%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range15.36 - 48.20 Perf YTD23.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.34% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low46.46% ATR1.73
Employees80 Current Ratio- Sales Q/Q-28.20% Oper. Margin- RSI (14)52.41 Volatility4.38% 7.15%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.06 Prev Close21.49
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume8.79K Price22.49
Recom- SMA2012.18% SMA50-3.10% SMA200-18.91% Volume9,329 Change4.68%
May-25-18Initiated Wells Fargo Outperform $44
Jan-07-19 01:00AM  Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS GlobeNewswire +7.22%
Dec-04-18 01:45AM  Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting GlobeNewswire -7.44%
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
01:00AM  Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101 GlobeNewswire
Nov-21-18 01:00AM  Celyad Announces Third Quarter 2018 Business Update GlobeNewswire
Nov-15-18 01:00AM  Celyad to Participate at Upcoming Healthcare Conferences GlobeNewswire
Nov-09-18 12:45PM  Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting GlobeNewswire
Nov-01-18 09:01AM  Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting GlobeNewswire +8.11%
Oct-05-18 08:48AM  Celyad (CYAD) Jumps: Stock Rises 6.8% Zacks
Oct-04-18 01:03AM  Celyad to Present CYAD-01 Solid Tumor Clinical Updates and Pre-Clinical Pipeline Data at the 2018 SITC Annual Meeting GlobeNewswire +5.29%
01:00AM  Celyad Announces Exclusive Agreement for Horizon Discoverys shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies GlobeNewswire
Sep-28-18 01:00AM  Transparency Notification of Victory Capital Management Inc. GlobeNewswire
Sep-26-18 01:00AM  Celyad Appoints Carri Duncan as Vice-President Corporate Development & Communications GlobeNewswire
Sep-25-18 01:00AM  Celyad to Participate at Upcoming Healthcare Conferences GlobeNewswire
Sep-05-18 01:00AM  Celyad Successfully Doses First Colorectal Cancer Patient With CYAD-01 Following Preconditioning Chemotherapy GlobeNewswire
Aug-23-18 01:00AM  Celyad Reports First Half 2018 Financial Results and Operational Progress GlobeNewswire +6.40%
Aug-07-18 01:00AM  Celyad Appoints Filippo Petti as Chief Financial Officer GlobeNewswire
Aug-01-18 01:00AM  Dr. Margo Roberts Joins Celyads Board of Directors and Scientific Committee GlobeNewswire
Jul-24-18 08:53AM  Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering Benzinga
01:00AM  Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate GlobeNewswire
Jul-02-18 02:55PM  HC Wainwright: Celyad's CAR-T Pipeline Has Potential Benzinga
Jun-27-18 09:43AM  What Are Analysts Saying About The Future Of Celyad SAs (EBR:CYAD)? Simply Wall St.
Jun-19-18 01:00AM  Celyad Doses First AML Patient at Final Dose Level in CYAD-01 THINK Trial and Begins Dosing First Patient With Second Cycle of Therapy GlobeNewswire +6.23%
May-23-18 01:00AM  Celyad Announces Closing of Global Offering GlobeNewswire
May-18-18 08:00AM  Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved Benzinga
May-17-18 09:02AM  Celyad announces pricing of $47.3 million global offering GlobeNewswire -7.79%
May-16-18 08:10AM  Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings Benzinga -8.04%
May-15-18 04:47PM  Celyad Announces First Quarter 2018 Business Update GlobeNewswire -7.49%
04:46PM  Celyad announces launch of proposed global offering GlobeNewswire
May-09-18 01:00AM  Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018 GlobeNewswire
May-03-18 01:00AM  Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials GlobeNewswire
Apr-27-18 10:42AM  What Should Investors Know About Celyad SAs (NASDAQ:CYAD) Growth? Simply Wall St. +15.71%
02:30AM  Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient GlobeNewswire
Apr-26-18 08:56AM  Celyad SA (EBR:CYAD): Whats The Analyst Consensus Outlook? Simply Wall St.
Mar-29-18 01:00AM  Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018 GlobeNewswire
Mar-22-18 04:01PM  Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018 GlobeNewswire
Oct-30-17 09:40AM  Edison Issues ADR Update on Celyad (CYAD) ACCESSWIRE
Sep-05-17 02:59PM  Celyad SA :CYAD-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017 Capital Cube
Aug-14-17 08:00AM  Edison Issues Update on Celyad (CYAD) ACCESSWIRE +5.74%
Jul-31-17 06:30AM  BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers PR Newswire
Jun-19-17 08:53AM  3 Biotech Stocks That More than Doubled Year to Date Zacks
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.